Why the study?
Most evidence for plant antioxidants in diabetic cardiomyopathy comes from animal and cellular experiments, clinical data are limited, and clinical application faces challenges like poor bioavailability and standardization.
Plant antioxidants offer a potential therapeutic strategy for diabetic cardiomyopathy by targeting oxidative stress, but clinical application is hindered by bioavailability and standardization issues.
Should not yet change DCM practice; leaves open efficacy of plant antioxidants pending clinical trials.
Diabetic cardiomyopathy (DCM), one of the most severe complications of diabetes, is closely associated with oxidative stress (OS) in its development and progression. Studies have shown that plant antioxidants play an important role in the prevention and treatment of DCM by modulating redox signaling and regulating the sources of reactive oxygen species (ROS) generation. However, most existing evidence comes from animal and cellular experiments, and clinical data are limited. In addition, their clinical application faces challenges, including poor bioavailability and difficulty in standardizing active ingredients. Therefore, this review focuses on the role of plant antioxidants in regulating myocardial oxidative stress and maintaining redox homeostasis, and explores their potential clinical applications and current limitations. This review aims to provide a theoretical basis and guidance for the prevention and treatment of DCM using plant antioxidants.
No takes yet. Share an insight, caveat, or question.
阴祖峰 et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: